https://tirzepatidewatchdog.comIndependent evidence and pricing research for medications, peptides and telehealth care.en-usTue, 14 Jul 2026 17:01:43 +0000https://tirzepatidewatchdog.com/blog/brand-glp1-price-collapse-2026https://tirzepatidewatchdog.com/blog/brand-glp1-price-collapse-2026Zepbound fell to $299. Wegovy to $349. The oral tablet to $149. The price gap that justified compounded GLP-1 has largely closed, and almost nobody is…Tue, 14 Jul 2026 17:01:43 +0000https://tirzepatidewatchdog.com/blog/compounded-vs-brand-decisionhttps://tirzepatidewatchdog.com/blog/compounded-vs-brand-decisionThe compounded case rested on a price gap that has largely closed. Here is how to decide now.Tue, 14 Jul 2026 17:01:43 +0000https://tirzepatidewatchdog.com/blog/flat-rate-vs-escalating-glp1https://tirzepatidewatchdog.com/blog/flat-rate-vs-escalating-glp1Some providers charge the same price at every dose. Others raise it as you titrate. Over a year, the gap can exceed $3,000.Tue, 14 Jul 2026 17:01:43 +0000https://tirzepatidewatchdog.com/blog/generic-pde5-vs-compoundedhttps://tirzepatidewatchdog.com/blog/generic-pde5-vs-compoundedBoth are FDA-approved and available as inexpensive generics. Compounded troches and 'proprietary blends' offer no demonstrated advantage.Tue, 14 Jul 2026 17:01:43 +0000https://tirzepatidewatchdog.com/blog/glp1-annual-cost-truthhttps://tirzepatidewatchdog.com/blog/glp1-annual-cost-truthMonthly figures are how this is marketed. Annual totals are how it is experienced. Every provider, twelve months, all in.Tue, 14 Jul 2026 17:01:43 +0000https://tirzepatidewatchdog.com/blog/glp1-dose-cap-warninghttps://tirzepatidewatchdog.com/blog/glp1-dose-cap-warningNoom's $199 semaglutide is capped at 0.6mg. The STEP trials used 2.4mg. That is not a discount - it is a different treatment.Tue, 14 Jul 2026 17:01:43 +0000https://tirzepatidewatchdog.com/blog/glp1-dosing-errorshttps://tirzepatidewatchdog.com/blog/glp1-dosing-errorsThe FDA has logged 1,700++ adverse events for compounded semaglutide and 320+ for tirzepatide. Dosing errors from self-measured vials are a recurring…Tue, 14 Jul 2026 17:01:43 +0000https://tirzepatidewatchdog.com/blog/glp1-insurance-guidehttps://tirzepatidewatchdog.com/blog/glp1-insurance-guideIf your plan covers Zepbound or Wegovy, a manufacturer savings card can bring it to roughly $25. Nothing on the cash market competes.Tue, 14 Jul 2026 17:01:43 +0000https://tirzepatidewatchdog.com/blog/how-to-verify-compounding-pharmacy-guidehttps://tirzepatidewatchdog.com/blog/how-to-verify-compounding-pharmacy-guideThe pharmacy matters more than the brand on the website. Seven questions, and what the answers tell you.Tue, 14 Jul 2026 17:01:43 +0000https://tirzepatidewatchdog.com/blog/intro-rate-traphttps://tirzepatidewatchdog.com/blog/intro-rate-trapTrimRx advertises $179. MEDVi advertises $179. Both charge $299 from month two. Here is how first-month pricing distorts every comparison table you…Tue, 14 Jul 2026 17:01:43 +0000https://tirzepatidewatchdog.com/blog/lillydirect-45-day-traphttps://tirzepatidewatchdog.com/blog/lillydirect-45-day-trapZepbound's $449 maintenance rate holds only if you refill within 45 days of your last delivery. Miss it and you pay $699.Tue, 14 Jul 2026 17:01:43 +0000https://tirzepatidewatchdog.com/blog/microdose-legal-loopholehttps://tirzepatidewatchdog.com/blog/microdose-legal-loopholeThe industry-wide pivot to microdosing tracks the end of FDA enforcement discretion almost exactly. That is not a coincidence, and nobody selling it…Tue, 14 Jul 2026 17:01:43 +0000https://tirzepatidewatchdog.com/research/surmount-1https://tirzepatidewatchdog.com/research/surmount-1Mean weight change: −15.0% (5mg), −19.5% (10mg), −20.9% (15mg), versus −3.1% with placebo.Tue, 14 Jul 2026 17:01:43 +0000https://tirzepatidewatchdog.com/research/surmount-5https://tirzepatidewatchdog.com/research/surmount-5Tirzepatide −20.2% (95% CI −21.4 to −19.1) versus semaglutide −13.7% (95% CI −14.9 to −12.6), p<0.001. Absolute: 22.8 kg versus 15.0 kg. At least 25% body-weight loss: 31.6% versusTue, 14 Jul 2026 17:01:43 +0000https://tirzepatidewatchdog.com/research/step-1https://tirzepatidewatchdog.com/research/step-1Mean weight change −14.9% with semaglutide versus −2.4% with placebo.Tue, 14 Jul 2026 17:01:43 +0000https://tirzepatidewatchdog.com/research/selecthttps://tirzepatidewatchdog.com/research/selectA 20% relative reduction in major adverse cardiovascular events (6.5% versus 8.0% absolute). This is the trial that moved semaglutide from a weight-loss drug to a cardiovascular onTue, 14 Jul 2026 17:01:43 +0000